Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Brexafemme (ibrexafungerp) is indicated for the treatment of adult and post-menarchal pediatric females for vulvovaginal candidiasis (VVC) and for reducing the incidence of recurrent vulvovaginal candidiasis (RVVC).
• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Clinical Cure Rate: Ibrexafungerp demonstrated a superior clinical cure rate with a risk ratio (RR) of 1.33 (95% CI: 1.07, 1.66) compared to fluconazole/placebo in the treatment of vulvovaginal candidiasis (VVC). However, in a phase 2 study, ibrexafungerp showed similar efficacy to fluconazole (51.9% vs. 58.3% clinical cure rates). Two phase 3 trials confirmed ibrexafungerp's superiority over placebo in moderate to severe VVC (P < 0.001 and P = 0.023).
• Mycological Eradication Rate: Ibrexafungerp exhibited a superior mycological eradication rate with an RR of 1.72 (95% CI: 1.00, 2.95) when compared to fluconazole/placebo.
• Overall Success Ratio: Ibrexafungerp showed a higher overall success ratio with an RR of 1.64 (95% CI: 0.92, 2.92) relative to fluconazole/placebo.
• The duration of treatment-related treatment-emergent adverse events (TEAE), including nausea and diarrhea, was significantly longer for patients treated with ibrexafungerp compared to fluconazole/placebo.
• Gastrointestinal-related symptoms were the most frequently reported adverse reactions in clinical trials for ibrexafungerp.
• There is no population types or subgroups information available in the reviewed studies.